Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 130Recurrence 34Lymphoma, Follicular 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Non-Hodgkin 23Neoplasms 13Lymphoma 13Lymphoma, Mantle-Cell 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hematologic Diseases 5Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Pyloric Stenosis, Hypertrophic 2Prostatic Neoplasms 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Leukemia-Lymphoma, Adult T-Cell 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10peginesatide 3luspatercept 3hematide 3ACE-011 3telapristone acetate 2ferric carboxymaltose 2Erythropoietin 2AP 1903 reagent 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2roxadustat 1iron isomaltoside 1000 1ferrous sulfate 1ferric gluconate 1continuous erythropoietin receptor activator 1angiotensin I (1-7) 1Sugars 1Standard of Care 1Solutions 1Population Groups 1NOX-H94 1Lenalidomide 1LY2787106 1Iron-Dextran Complex 1Injections 1Infliximab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia × Lenalidomide × Clear all
NCT00179621 2011-04-14

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Celgene

Phase 3 Completed
205 enrolled 25 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡